Oxygen Biotherapeutics Sets Year-End Financial Results Conference Call and Webcast for July 25th and General Annual Meeting for August 31st
28 juin 2012 13h30 HE
|
Oxygen Biotherapeutics, Inc.
MORRISVILLE, N.C., June 28, 2012 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) today announced that it plans to report fiscal-year 2012 financial results on Form 10-K on Tuesday, July...
Oxygen Biotherapeutics Announces Expected Closing on Second Installment of December 2011 Financing and Amends Agreement to Allow for a Third Tranche Later This Year Pending Shareholder Approval
15 juin 2012 08h05 HE
|
Oxygen Biotherapeutics, Inc.
MORRISVILLE, N.C., June 15, 2012 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) today announced that it has entered into definitive agreements with institutional investors to amend the...
Oxygen Biotherapeutics Study Reveals Dermacyte(R) Concentrate's Potential to Relieve Histamine-Induced Pruritus in Healthy Patients
31 mai 2012 09h38 HE
|
Oxygen Biotherapeutics, Inc.
MORRISVILLE, N.C., May 31, 2012 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) announced today that data from its clinical study to determine the efficacy of Dermacyte® in...
Oxygen Biotherapeutics Secures Long-Term Clinical Supply of Oxycyte(R)
03 mai 2012 10h47 HE
|
Oxygen Biotherapeutics, Inc.
MORRISVILLE, N.C., May 3, 2012 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT), a development stage biomedical company ("the Company") focused on developing perfluorocarbon-based...
Oxygen Biotherapeutics Reports Financial Results for the Third Quarter FY2012
15 mars 2012 22h21 HE
|
Oxygen Biotherapeutics, Inc.
MORRISVILLE, N.C., March 15, 2012 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT), a development stage biomedical company focused on developing oxygen-rich intravenous and topical...
Oxygen Biotherapeutics Announces Plan to Regionalize Its Sales & Marketing Efforts for Its Dermacyte(R) Oxygenating Skin Care Product Line
01 mars 2012 16h44 HE
|
Oxygen Biotherapeutics, Inc.
MORRISVILLE, N.C., March 1, 2012 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) today announced that the Company has modified its sales and marketing effort to focus on the regional...
Oxygen Biotherapeutics and Aurum Biosciences Enter Joint Research Agreement to Develop an Oxycyte(R)-Based Diagnostic Tool and Therapeutic for Acute Ischemic Stroke
01 févr. 2012 07h30 HE
|
Oxygen Biotherapeutics, Inc.
MORRISVILLE, N.C., Feb. 1, 2012 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) and privately held Aurum Biosciences Ltd. of Glasgow, Scotland, today jointly announced they have signed...
Oxygen Biotherapeutics to Begin Clinical Study to Determine Efficacy of Dermacyte(R) in Relieving Histamine Induced Pruritus
09 janv. 2012 08h00 HE
|
Oxygen Biotherapeutics, Inc.
MORRISVILLE, N.C., Jan. 9, 2012 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) announced today that enrollment for the company's first dermatological study...
Oxygen Biotherapeutics Names Two New Board Members With Pharmaceutical Industry, Product and Business Development Emphasis
19 déc. 2011 09h20 HE
|
Oxygen Biotherapeutics, Inc.
MORRISVILLE, N.C., Dec. 19, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced it has named Chris A. Rallis, Executive-in-Residence at...
Oxygen Biotherapeutics Reports Second Quarter FY2012 Financial Results
16 déc. 2011 13h33 HE
|
Oxygen Biotherapeutics, Inc.
MORRISVILLE, N.C., Dec. 16, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX:OXBT), a development stage biomedical company focused on developing oxygen-rich intravenous and...